Exagen (XGN) Set to Announce Quarterly Earnings on Monday

Exagen (NASDAQ:XGN) is scheduled to release its earnings data before the market opens on Monday, May 13th. Analysts expect Exagen to post earnings of ($0.40) per share for the quarter. Exagen has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Exagen (NASDAQ:XGN) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.02). The company had revenue of $13.77 million during the quarter, compared to analysts’ expectations of $11.43 million. Exagen had a negative net margin of 45.08% and a negative return on equity of 80.28%. During the same period in the previous year, the company posted ($0.58) earnings per share. On average, analysts expect Exagen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Exagen Trading Up 0.1 %

NASDAQ XGN opened at $1.40 on Monday. The firm has a market capitalization of $24.32 million, a P/E ratio of -1.04 and a beta of 1.20. The business has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.75. Exagen has a 12 month low of $1.30 and a 12 month high of $3.92. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.85.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).